MALT1

mucosa associated lymphoid tissue lymphoma translocation gene 1

MALT1 is a paracaspase, which is related to the caspase (cysteine-aspartic proteases) family of proteases but cleaves after Arg residues instead of Asp. MALT1 cleavage activity is linked to the pathogenesis of activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL), a chemoresistant form of DLBCL. MALT1 is a unique paracaspase protein that transduces aberrant oncogenic signaling in ABC-DLBCL. MALT1 represents a potentially important therapeutic target for ABC-DLBCL and MALT lymphoma. MALT1 small molecule inhibitors might be useful chemical tools for studying MALT1 biology and treating MALT1-addicted tumors.

MALT1 Inhibitors

(R)-MALT1-IN-3

Cat. No.: HY-143422A

(R)-MALT1-IN-3 (compound 121) is a potent **MALT1 protease** inhibitor with an **IC_{50}** of 20 nM. (R)-MALT1-IN-3 has IC_{50} of 60 nM, 40 nM for human IL6/IL10 in OCI-LY3 cells, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-MALT1-IN-7

Cat. No.: HY-143425A

(R)-MALT1-IN-7 (compound 142a) is a potent **MALT1 protease** inhibitor. (R)-MALT1-IN-7 has&n bsp;the potential for cancer r esearch.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-MLT-985

Cat. No.: HY-142648A

(R)-MLT-985 (compound 11) is a potent **MALT1 protease** inhibitor with an **IC_{50}** of 3 nM. (R)-MLT-985 has an IC_{50} of 20 nM for MALT1-dependent IL-2 production in Jurkat cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-MALT1-IN-5

Cat. No.: HY-143423A

(S)-MALT1-IN-5 is a potent inhibitor of **MALT1** protease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JNJ-67856633

Cat. No.: HY-139399

JNJ-67856633 is an orally active, first-in-class, potent, selective and allosteric **MALT1 protease** inhibitor. JNJ-67856633 in some cases lead to tumor stasis.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MALT1 inhibitor MI-2

Cat. No.: HY-12276

MALT1 inhibitor MI-2 is a **MALT1** inhibitor (**IC_{50}**=5.84 μM).



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MALT1-IN-7

Cat. No.: HY-143425

MALT1-IN-7 (compound 142b) is a potent **MALT1 protease** inhibitor. MALT1-IN-7 has the potential for cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mepazine

(Pecazine)

Cat. No.: HY-121282

Mepazine (Pecazine) is a potent and selective **MALT1** protease inhibitor with **IC_{50}**s of 0.83 and 0.42 μM for GSTMALT1 full length and GSTMALT1 325-760, respectively. Mepazine affects viability of ABC-DLBCL cells by enhancing **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mepazine hydrochloride

(Pecazine hydrochloride)

Cat. No.: HY-121282A

Mepazine hydrochloride (Pecazine hydrochloride) is a potent and selective **MALT1** protease inhibitor with **IC_{50}**s of 0.83 and 0.42 μM for GSTMALT1 full length and GSTMALT1 325-760, respectively. Mepazine hydrochloride affects viability of ABC-DLBCL cells by enhancing **apoptosis**.



Purity: 98.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg, 250 mg

MLT-231

Cat. No.: HY-131902

MLT-231 is a potent, highly selective allosteric **MALT1** Inhibitor with an **IC_{50}** of 9 nM. MLT-231 specifically prevents endogenous BCL10 cleavage with IC_{50} of 160 nM. MLT-231 shows antitumor activity in an ABC-DLBCL type xenograft model in mouse.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

MLT-747

Cat. No.: HY-124587

MLT-747 is a potent, selective, allosteric inhibitor of **MALT1**, binds MALT1 in the allosteric Trp580 pocket, with an IC_{50} of 14 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MLT-748

Cat. No.: HY-115466

MLT-748 is a potent, selective and allosteric inhibitor of **MALT1**, binds MALT1 in the allosteric Trp580 pocket, with an IC_{50} of 5 nM.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MLT-943

Cat. No.: HY-134820

MLT-943 is a potent, selective and orally active **MALT1 protease** inhibitor. MLT-943 inhibits stimulated-IL-2 secretion in PBMC or in whole blood with a similar IC_{50} across species (0.07-0.09 μM in PBMC, 0.6-0.8 μM in whole blood).



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MLT-985

Cat. No.: HY-142648

MLT-985 is a highly selective allosteric **MALT1** inhibitor with an IC_{50} value of 3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Z-VRPR-FMK TFA

(VRPR)

Cat. No.: HY-P1407

Z-VRPR-FMK (TFA) (VRPR), a tetrapeptide, is a selective and irreversible **MALT1** (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor. Z-VRPR-FMK (TFA) can protect against **influenza A virus (IAV)** infection.



Purity: 95.92%
Clinical Data: No Development Reported
Size: 500 μg